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1  | INTRODUC TION
Dyslipidaemia, including elevated total cholesterol, is a lipoprotein 
metabolism disorder that results from overproduction or deficiency of 
lipoproteins.1 It is a feature of metabolic syndrome, in which a com-
bination of medical disorders indicate a patient has greater risk of 
developing atherosclerosis.2 Cardiovascular disorders are now known 
as the world's leading cause of death and disability; in 2015, it is esti-
mated that more than 17 million deaths were attributed to cardiovas-
cular disease, amounting to 31% of all deaths worldwide.3 The use of 
statin in Palestine is very common. In a retrospective study on 386 hos-
pitalised patients, 113 (29.3%) had a documented previous statin use.
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Abstract
Aims: Strong evidence indicates that drugs reduce blood lipids and improve cardio-
vascular end-points, leading to their wide usage. However, the success of these drugs 
can be affected by poor patient's adherence to prescribed medication. This study 
aimed to evaluate medication adherence in patients with dyslipidaemia in association 
with patient beliefs about medicines.
Methods: The study was conducted from January 2019 to July 2019 at the mid-
dle governmental primary healthcare clinics in Ramallah and Bethlehem cities, and 
used	a	cross-sectional	design.	Adherence	was	determined	using	the	4-item	Morisky	
medication adherence scale, while beliefs were determined using the Beliefs about 
Medicines	Questionnaire.
Results: Of 220 patients, 185 agreed to participate in the study, resulting in a re-
sponse	rate	of	84.1%.	Of	the	participants,	106	(57.3%)	were	men,	and	almost	half	(88,	
46.5%)	were	≥56	years.	Medication	non-adherence	was	high	(47.6%),	but	a	majority	
(65.5%) reported believing their treatment to be necessary for their continued good 
health.	Accordingly,	the	mean	necessity	score	(17.3,	SD	3.7)	significantly	outweighed	
(P	<	 .001)	the	mean	concerns	score	 (14.0,	SD	3.5).	Multivariate	regression	demon-
strated four variables to be significantly correlated with non-adherence: illiterate 
(OR	=	2.52;	CI:	0.9-4.3;	P = .03), polypharmacy (OR = 3.18; CI: 1.9-5.7; P = .007), 
having	comorbidity	(OR	=	3.10;	CI:	2.2-4.6;	P = .005) and having concerns about side 
effects	(OR	=	2.89;	CI:	1.1-4.6,	P	=	.04).
Conclusion: Non-adherence among patients taking lipid-lowering agents was high de-
spite most holding positive beliefs regarding medication necessity. This may be due to 
concern also being high. Physicians should identify and target high-risk patients and in-
dividualise their treatment plans in order to achieve adequate control of dyslipidaemia.
2 of 8  |     SHAKARNEH Et Al.
In treatment of chronic diseases, non-adherence to medication reg-
imens is a key concern that can negatively impact treatment response, 
mortality and healthcare cost; consequently, this leads to elevated risk 
of hospitalisation, wasted resources, increased severity of disease and a 
need for more intense medicines.4	Medication	adherence,	the	extent	to	
which a patient take his medication as prescribed,5 is a multidimensional 
process to which many factors contribute.6 Factors related patients can 
include forgetfulness, interfering priorities, deliberately choosing to 
skip doses, being insufficiently informed and emotional considerations. 
Factors	related	to	health	provider	can	include	the	complexity	of	the	medi-
cation regimen, insufficient education of patients on benefits and side ef-
fects, failure to consider the patient's lifestyle or medication cost, and the 
lack of a good therapeutic relationship with the patient. Finally, factors 
related to healthcare system can include limited access of the patient to 
healthcare services, and the drugs and/or copayments having high costs.
The most powerful predictor of adherence is patient's be-
liefs about their medicine, which multiple studies have shown to 
be significantly associated with adherence.7,8	 As	 described	 by	 the	
Necessity-Concerns Framework, medication adherence is primar-
ily	 affected	 by	 the	 patient's	 expectation	 that	 their	 medication	 is	
required to maintain good health (necessity beliefs) and by worries 
about potential side effects (concerns beliefs).9
To improve the overall outcome of dyslipidaemia treatment, it 
is important to evaluate medication adherence and patient beliefs 
about medication, and furthermore, to recognise factors affecting 
adherence.10 Nevertheless, in our setting, there is a lack of research 
on both adherence and patient beliefs. The goal of this study was 
to address this research deficit in patients with dyslipidaemia and 
to additionally evaluate the association of patient beliefs and other 
factors with medication adherence.
2  | AIM OF THE STUDY
This study aims to identify predictors of adherence to dyslipidaemia 
medication regimens, which will help to improve patient's adher-
ence and enhance awareness about the importance of lipid-lowering 
medications in those at high risk for coronary artery disease.
3  | METHODS
3.1 | Study design
This cross-sectional study was carried out between January and July 
2019 at two middle governmental primary healthcare clinics in the 
cities of Ramallah and Bethlehem.
3.2 | Ethical approval
Before the initiation of this study, all aspects of the protocol were 
authorised	by	the	Research	Ethical	Committee	of	Al-Quds	University	
(ref no. 86/REC/2019) and by local health authorities at the study 
sites. The patients gave verbal consent forms before completing the 
questionnaires.
3.3 | Sample size and participants
Raosoft (http://www.raoso ft.com/sampl esize.html) was used to 
estimate the necessary sample size; 170 patients from both clinics 
participated in the study. Participants were recruited by means of 
convenience sampling and were selected from patients who were 
provided with medical care and anti-hyperlipidaemia medications 
at	 the	 selected	 healthcare	 centres	with	 regular	 follow-up.	A	well-
trained clinical pharmacist who works in a pharmacy clinic at the pri-
mary care conducted the interview.
Patients were included in the study if they: (a) were at least 18 years 
old;	(b)	were	able	to	read	or	understand	Arabic;	(c)	were	willing	to	take	
part in the study; (d) were diagnosed with dyslipidaemia at least 1 year 
prior; (e) were currently being treated for dyslipidaemia and (f) these are 
lab results should be available in patients' file and recordas mentioned 
in your previous question: lipoprotein (LDL) and total cholesterol.
3.4 | Measurement
The survey used contained four sections: socio-demographic fac-
tors	obtained	directly	from	patients;	Morisky	medication	adherence	
scale	(MMAS-4);	the	Beliefs	about	Medicines	Questionnaire	(BMQ);	
and clinical variables obtained from patient medical files.
In	 the	 MMAS-4,	 all	 questions	 had	 dichotomous	 responses	
(No	=	0	and	Yes	=	1).	Total	scores	were	summed	 (range	0-4),	with	
scores	of	0-1	denoting	high	adherence	and	2-4	denoting	low	adher-
ence.11	The	MMAS	is	perhaps	the	most	widely	accepted	instrument	
for measuring self-reported medication adherence.12
What's known
• Dyslipidaemia is one of the most common disorders en-
countered in patient consultations and non-adherence to li-
pid-lowering agents could lead to adverse clinical outcomes.
• Low or non-adherence to lipid-lowering medications is 
common. However, the reasons for poor adherence are 
not well understood.
What's new
• Non-adherence among patients taking lipid-lowering 
drugs was high despite most holding positive beliefs re-
garding medication necessity.
• Being illiterate, polypharmacy, comorbidities and con-
cerns about side effects are significantly associated with 
non-adherence.
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The	BMQ	was	developed	by	Horne	et	al,13	and	its	Arabic	version	
was validated for patients with chronic illness in 2012.14 This survey is 
composed of two 5-item scales; one assesses the perceived necessity 
of a medication for control of the patient's illness and the other con-
cerns of adverse consequences from the medication. On both scales, 
each item is scored 5 to 1 (strongly agree to strongly disagree), with a 
higher score representing greater belief or concern; summing along a 
scale gives a total value of 5 to 25. Subtracting concern from neces-
sity	gives	the	necessity-concerns	differential	(NCD)	score	(−20	to	20),	
where a positive value indicates that the patient perceives medication 
benefits to outweigh risks and a negative value the inverse.15
Patients were additionally categorised into four attitudinal pro-
files by dividing the scales at their midpoints (ie 15): ‘indifferent’ 
(both concern and necessity are low), ‘sceptical’ (concern high, ne-
cessity low), ‘accepting’ (necessity high, concern low) and ‘ambiva-
lent’ (both concern and necessity are high).16
3.5 | Statistical analysis
All	data	were	coded	and	entered	into	SPSS,	version	21	for	all	analyses.	
Continuous	variables	(eg	age,	number	of	medications)	were	expressed	
as mean and standard deviation and categorical variables as frequen-
cies	(percentages).	The	Kolmogorov-Smirnov	test	was	used	to	evaluate	
the normality of each variable. For categorical variables, significance 
was	determined	by	either	chi-squared	or	Fisher's	exact	test;	category	
means	were	tested	for	significant	differences	by	Mann-Whitney	test.	A	
value of P < .05 was considered significant for analysis.
4  | RESULTS
4.1 | Patient characteristics
Of the 220 patients approached for this study, a total of 185 
agreed	to	take	part	 (response	rate	84.1%).	Of	the	185	responders,	
106	(57.3%)	were	men.	Almost	half	of	the	participants	 (88,	46.5%)	
were	 ≥56	 years	 of	 age;	 79.7%	widow;	 42.7%	were	 not	 educated;	
and	 64.1%	 described	 themselves	 as	 religious.	 Two-thirds	 of	 par-
ticipants	(65.4%)	reported	school	education,	while	only	22.2%	were	
educated	at	the	college	or	university	 level.	Also,	119	(64.32%)	had	
been prescribed with more than four drugs. Nearly all patients were 
taking statins (168, 90.80%) and had done so for an average dura-
tion	of	 8.6	±	4.7	 years;	 the	mean	 total	 cholesterol	 of	 participants	
was 263.1 ± 52.1 mg/dL. Participant characteristics are detailed in 
Table 1.
4.2 | Non-adherence behaviours
In this study population, medication non-adherence as captured by 
4-item	MMAS	was	 high	 (47.6%).	 Univariate	 analysis	 revealed	 that	
non-adherence was most likely among illiterate patients (P = .03), 
those on more than four drugs (P < .001) and those having comorbid-
ities (P < .001) (Table 1). Non-adherence was most commonly attrib-
uted to forgetfulness (35.2%), and second-most to insufficient care 
about taking medications (27.3%). Non-adherence was commonly 
unintentional (70.5%), and less often either intentional (26.1%) or 
mixed	in	intent	(20.5%)	(Table	2).
4.3 | Beliefs about medicines
Among	 participants	 in	 this	 study,	 a	 majority	 (65.5%)	 reported	 a	
strong beliefs in the necessity of their current treatment to maintain 
good health (ie not become ill). Lipid-lowering medications were ad-
ditionally regarded as important for ensuring future health by most 
(52.7%) of the participants (Figure 1).
However, despite these beliefs, 60.1% of participants also re-
ported concerns about their lipid-lowering medications having 
long-term	or	adverse	effects.	Overall,	most	participants	(54%)	were	
concerned about becoming dependent on lipid-lowering agents. 
There was much less concern about the medications disturbing their 
lives (Figure 2). Notably, the mean concern score of 13.21 (SD 3.2) 
was significantly below the mean necessity score of 17.92 (SD 3.2; 
P	<	.001),	for	a	mean	necessity-concern	differential	of	4.7	(SD	1.4).	
However, individual necessity scores were lower (ie NCDs were neg-
ative) for 33 participants (17.8%), while equal scores were obtained 
for	8	participants	(4.3%).
To group participants, their beliefs were categorised as high or 
low relative to the scale midpoints (specific-necessity and specif-
ic-concerns), defining four attitudinal categories: accepting—high 
necessity, low concern (93, 50.3%); ambivalent—high necessity, 
high	 concern	 (48,	 25.9%);	 sceptical—high	 concern,	 low	 necessity	
(19, 10.3%) and indifferent—low concern, low necessity (25, 13.5%) 
(Figure 3).
Chi-squared analysis showed significant variation in non-adher-
ence across attitudinal groups, χ2	(3,	n	=	185)	=	13.47,	P	=	.004.	A	ma-
jority (60.8%) of adherent patients were accepting, compared with 
38.6% of the non-adherent group. In contrast, 78.9% of non-adher-
ent patients were sceptical, compared with 21.1% of the adherent 
group.
4.4 | Association of beliefs with other factors
Analysis	revealed	that	adherent	patients	more	strongly	believed	they	
had	personal	need	of	 lipid-lowering	drugs.	Meanwhile,	non-adher-
ent participants possessed stronger concerns about long-term use 
of medications and potential adverse events in the future (Table 3). 
The NCD score of non-adherent participants was lower than that of 
adherent	participants	(4.7	vs	1.7,	P < .001), revealing that for non-ad-
herent participants belief in the need for lipid-lowering agents was 
similar to concern about long-term use of the medications.
Table	 4	 gives	 additional	 results	 correlating	 necessity	 scores	
with patient characteristics. The mean necessity score for men was 
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not significantly greater than that of women (17.7 vs 16.8, P	=	.14).	
However, a significant negative correlation was observed when 
considering total cholesterol (P	=	.03)	or	Morisky	score	(P = .01). No 
significant association was identified that connected any other de-
mographic or clinical variables with necessity scores.
Unlike	 necessity	 scores,	 concern	 scores	 were	 found	 to	 have	
significant associations with demographic and clinical variables 
(Table 5). Namely, significant positive correlations were identified 
with the number of medications being taken (P	=	.01)	and	Morisky	
score (P = .01). No significant correlations were identified for other 
demographic or clinical variables.
Associations	of	independent	variables	with	low	adherence	were	
predicted using a stepwise multivariate logistic regression model 
(Table 6). Four variables were identified as significant and associ-
ated	with	 non-adherence:	 illiterate	 (OR	 =	 2.52;	 CI:	 0.9-4.3),	 poly-
pharmacy (OR = 3.18; CI: 1.9-5.7), having a comorbidity (OR = 3.10; 
Variable n (%)
All patients 
(185)
High 
adherence (97)
Low adherence 
(88) P-value
Gender
Male 106 (57.3) 55 (56.7) 51 (57.9) .61a 
Female 79	(42.7) 42	(43.3) 37	(42.04)  
Age
18-35 y 22 (11.9) 9 (9.3) 13	(14.8) .11a 
36-55 y 77	(41.6) 35 (36.1) 42	(47.7)  
≥56	y 86	(46.5) 41	(42.3) 45	(51.1)  
Education level
Illiterate 23	(12.4) 8	(8.24) 15	(17.04) .03a 
School level 121	(65.4) 66	(68.04) 57	(64.8)  
College/university level 41	(22.2) 29 (29.89) 16 (18.2)  
Living status
Living alone 19 (10.27) 7 (7.22) 12	(13.64) .06a 
Living with someone 166 (89.73) 90 (92.78) 76 (86.36)  
BMI
Normal 66 (35.68) 38 (39.28) 28 (31.82) .45a 
Overweight 89	(48.12) 48	(49.5) 44	(50.0)  
Obese 30 (16.22) 11	(11.34) 19 (21.59)  
Polypharmacy
<4 119	(64.32) 69 (71.13) 50 (56.82) <.001a 
>4 66 (35.68) 28 (28.87) 38	(43.18)  
Comorbidities
Yes 125 (67.57) 55 (56.70) 70	(79.54)  
No 60	(32.43) 42	(43.29) 18	(20.45) <.001a 
Medications
Statins 168 (90.80) 90 (92.8) 78 (88.6) .55
Fibrates 15 (8.21) 7 (7.2) 8 (9.0)  
Others 2 (1.1) 0 2	(2.4)  
Duration of statin use 
(years ± SD)
8.6	±	4.7 7.3	±	4.1 8.8	±	4.4 .06b 
Total cholesterol (mg/
dL ± SD)
263.1 ± 52.1 256.8 ± 50.5 269.9 ± 53.2 .07b 
LDL-C (mg/dL ± SD) 140.0	±	18.1 140.6	±	18.3 137.7 ± 17.9 .63b 
HDL-C (mg/dL ± SD) 53.2 ± 6 54.1	±	6.6 53.1	±	5.4 .71b 
Total	Morisky	score	(±SD) 1.4	±	0.5 0.961 ± 0.17 2.0 ± 0.3 <.00b 
Note: Total	Morisky	score	range	1-4.
Abbreviations:	HDL,	high-density	lipoprotein;	LDL,	low-density	lipoprotein.
aChi-squared test for categorical groups. 
bStudent's t test. 
TA B L E  1   Patient characteristics and 
univariate analysis results reflecting 
potential contributions of characteristics 
to medication adherence
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CI:	2.2-4.6)	and	having	concerns	about	side	effects	(OR	=	2.89;	CI:	
1.1-4.6).
5  | DISCUSSION
For this analysis, patients were only considered adherent if scored 
as high adherence (score of 0-1); those who scored >1 were consid-
ered	 to	have	 low	adherence.	More	 than	90%	of	participants	were	
taking	 statins,	 and	 47.6%	 self-reported	 low	 adherence.	 Our	 find-
ings are inconsistent with previous studies, which determined that 
30%-50% of patients stopped taking lipid-lowering medication and 
that adherence decreases over time.17 The most likely causes of low 
adherence in our sample were unintentional forgetfulness and care-
lessness in taking medications, which were reported by 35.2% and 
27.3% of patients, respectively. However, nearly a fifth of patients 
(19.3%) reported intentional non-adherence in that they stopped 
taking their medications upon feeling better. The overall non-
adherence	rate	 (46.7%)	 in	this	study	concurs	with	prior	reports	by	
Elsous et al (52.3%),18 Jackson et al (51.2%)19 and Bizu et al (51%).20 
However, lower adherence rates have also been reported by Sweileh 
et al21 and Jamous et al,22	at	16.9%	and	42.7%,	respectively.
In this study population, non-adherence was primarily caused 
by unintentional behaviours, most commonly forgetfulness and 
carelessness about medication time.23	Reasonable	explanations	for	
these behaviours may be attributed to multiple factors, including 
work, travelling, economic status and lack of effectiveness or ad-
verse effects of the medications.24
The main finding concerning beliefs about medicines was that the 
majority of patients having dyslipidaemia hold strong beliefs with re-
gard to medication necessity (mean necessity score 17.3). However, 
a	 high	 proportion	 of	 participants	 also	 expressed	 concerns	 about	
long-term	and	potential	adverse	effects.	A	general	practice	survey	
in France, revealed that more than 10% of patients with dyslipidae-
mia receiving high-dose statins reported myopathy symptoms.25 
Another	study	in	the	United	States	called	(USAGE)	reported	myopa-
thy side effects in 60% of current and 25% of former users, with side 
effects the primary reason for statin discontinuation (62%).26 The 
importance of patient perception of side effects in adherence has 
been demonstrated by several studies,27 and non-adherence may be 
particularly likely for patients on high doses of cholesterol-lowering 
drugs	who	experience	adverse	events.28
In this study, no association was identified connecting necessity 
score with the demographic variables of age, duration of dyslipidae-
mia or the number of drugs being taken. However, necessity scores 
were	 negatively	 associated	with	mean	Morisky	medication	 adher-
ence (low score meaning higher adherence) and with total blood 
cholesterol level. This finding is reasonable as better adherence with 
lipid-lowering agents will result in a decrease of total cholesterol in 
the	blood.	Meanwhile,	significant	and	positive	associations	with	con-
cern	scores	were	observed	for	Morisky	score,	high	blood	cholesterol	
level, and number of medications taken. Our findings are in consis-
tence	with	prior	reports	in	US	specialist	care	and	in	the	context	of	
various long-term conditions.
TA B L E  2  Adherence	and	non-adherence	among	study	
participants (n = 185)
Prevalence of adherence/non-adherence Total 185 (%)
Adherent	patients 97	(52.4)
Non-adherent patients 88	(47.6)
Likely cause of non-adherence Total 88 (%)
Forgetting to take medication 31 (35.2)
Careless at times about taking medications 24	(27.3)
Feeling better 17 (19.3)
Feeling worse 13	(14.7)
Type of non-adherence behaviour Total 88 (%)
Unintentional 62 (70.5)
Intentional 23 (26.1)
Mixed 18 (20.5)
F I G U R E  1   Respondent agreement (agree/strongly agree) with 
questionnaire statements (necessity statements)
65.5%
61.2%
52.7%
49.3%
42.6%
0.0% 20.0% 40.0% 60.0% 80.0%
Without my medicines I would become very
ill
My medicines protect me from becoming
worse
My health in the future will depend on my
medicines
My health at present , depends on my
medicines
My life would be impossible without my
medicines
TA B L E  3   Necessity and concern scores for adherent and non-adherent patients
Score
Adherent
Mean (SD)
Non-adherent
Mean (SD) t (df) Mean difference 95% CI P-value*
Necessity score 17.92 (3.2) 16.63	(4.1) 2.4	(185) 1.29 0.23-2.3 .018
Concerns score 13.21 (3.2) 14.91	(3.7) −3.3	(185) −1.69 −2.70	to	−0.68 .001
NCD 4.7	(1.4) 1.7 (0.16) 3.5 (185) 2.96 1.33-4.54 .001
Abbreviations:	CI,	confidence	interval;	df, degrees of freedom; NCD, necessity-concerns differential; SD, standard deviation.
*t test. 
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Patient adherence was further evaluated in terms of attitude by 
combining necessity and concern ratings in a two-dimensional anal-
ysis. Half of the participants (50.3%) classified as accepting of their 
lipid-lowering agents (high necessity, low concern). Participants who 
were classified as sceptical (high concern, low necessity) were more 
likely to have low adherence.
Logistic regression revealed several factors predictive of non-ad-
herence behaviours: illiteracy and low education (at most through 
primary school) were the most likely predictors (P	=	.03).	Many	pre-
vious studies have similarly reported higher rates of non-adherence 
among patients of lower education levels.29,30 Lower education is 
also associated with lower socio-economic status, poor access to 
the health system and less knowledge about their disorder.31 Thus, 
providing more accessible facilities and arranging educational and 
training programs can improve treatment adherence.32
Polypharmacy (having more than four drugs prescribed) was 
found to be highly predictive of non-adherence (P	 =	 .007).	 A	 re-
view analysis by Zelko et al33 found that for polypharmacy patients, 
non-adherence rates ranged from 6% to 55%. Valladolid et al have 
found negative associations of medication adherence with more 
drugs being taken, a large cost burden.34 In the present study, co-
morbidity was another highly significant predictor of non-adherence 
(P = .005). Our findings are consistent with the literature, which have 
reported	association	of	comorbidities	with	depression,	anxiety	and	
stress, which then have negative effects on adherence.35
The last independent predictor of non-adherence identified in 
this analysis was concern about medications (P	 =	 .04),	 consistent	
with prior literature.36 Consideration of patient concerns may be 
essential in ensuring adherence and effective use of medication; pa-
tient concerns have been found to predict non-adherence in terms 
of	both	extent	and	direction	(over-	or	underuse).37
When developing strategies to improve adherence, modifiable 
factors should be addressed, and the patients targeted should be 
those most likely to not adhere. However, the currently available 
literature on adherence is highly heterogeneous; efforts are first 
needed to improve the standardisation and therefore comparability 
of adherence studies.
F I G U R E  2   Respondent agreement (agree/strongly agree) with 
questionnaire statements (concern statements)
60.1%
54.1%
48.4%
24.4%
21.7%
0.0% 20.0% 40.0% 60.0% 80.0%
I somemes worry about the long term effects
of my medicines
I some worry about becoming too dependent
on my medicines
Having to take medicines worries me
My medicines disrupt my life
My medicines are a mystery to me
F I G U R E  3   Classification groups describing patient attitudes 
toward their medications
c
n n
c
TA B L E  4  Association	of	participant	characteristics	with	
necessity scores
Variables N
Pearson's 
correlation P-value
Age	(y,	SD) 185 0.059 .49
Duration of statin use (y) 185 0.042 .61
Number of medications taken 185 −0.144 .09
Total cholesterol (mg/dL) 185 −0.21 .03
LDL-C (mg/dL) 185 0.11 .13
Mean	Morisky	adherence	score 185 −0.38 .01
TA B L E  5  Association	of	participant	characteristics	with	concern	
scores
Variables N
Pearson's 
correlation P-value
Age	(y,	SD) 185 0.03 0.69
Duration of statin use (y) 185 0.12 0.18
Number of medications taken 185 0.33 0.01
Total cholesterol (mg/dL) 185 0.34 0.01
LDL-C (mg/dL) 185 0.067 0.44
Mean	Morisky	adherence	score 185 0.43 0.01
TA B L E  6  Multiple	regression	analysis	for	variables	predicting	
non-adherence
 Β OR CI P-value
Education (illiterate) 0.924 2.52 0.9-4.3 .032
Living alone 0.285 1.33 0.5-2.7 .157
Polypharmacy	>	4 1.157 3.18 1.9-5.7 .007
Duration of statin 
use > 5 y
0.599 1.44 1.3-3.3 .093
Having comorbidity 1.410 3.10 2.2-4.6 .005
Having concerns 
about side effects
1.06 2.89 1.1-4.4 .043
Necessity score < 15 0.322 1.38 0.6-3.3 .113
Abbreviations:	β, regression coefficient; CI, confidence interval; OR, 
odds ratio.
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Patient education and information have been shown to lead to 
enhanced knowledge and improved lipid-control behaviours.38,39	A	
systematic review of seven studies involving educational and knowl-
edge interventions40 found that participants who received an inter-
vention were more adherent than those who received only usual 
care (odds ratio 1.93, 95% confidence interval 1.29-2.88).
The results of this work indicate that patients with risk factors 
pay	more	attention.	Accordingly,	patient	beliefs	about	 the	 risks	of	
high cholesterol and the severity of high cholesterol are significantly 
associated with medication compliance, and adherence then rein-
forces the beliefs.41 Other studies have reported that patient beliefs 
about the importance of cholesterol in heart disease incidence will 
increase	 patient	 motivation	 and	 increase	 adherence.	 Meanwhile,	
patients who lack understanding of the risks associated with high 
cholesterol may be less likely to believe the condition is serious and 
that aggressive treatment is necessary.42
Pharmacists can enhance adherence among patients with dys-
lipidaemia.	A	number	of	interventions	that	involve	pharmacists	have	
been documented in the literature, including counselling visits at 
the pharmacy,42 making phone calls and leaving voice messages,43 
telephone counselling coordinated by a computer-based tracking 
system,44 and preparing a ‘beep card’ to provide reminders when a 
dose is due.
5.1 | Strength and limitations
This study was unique in classifying attitudes of patients having dys-
lipidaemia towards their medications as four attitudinal categories: 
accepting (high necessity/low concern), ambivalent (high concern/
high necessity), sceptical (high concern/low necessity) and indiffer-
ent (low concern/low necessity).
Surveys and self-reported methods have potential limitations, 
which are prone to recall biases and/or overestimation of adherence 
rate may have occurred. Due to the nature of the study as a ques-
tionnaire-based	study,	explaining	the	cause	and	effect	of	non-adher-
ence is limited. Finally, the study covered only two medical centres, 
which may lack generalisability of our findings.
6  | CONCLUSION
This study contributes to the increasing evidence suggesting that 
patient concerns and beliefs about medication are associated with 
adherence behaviour. In addition, direction of non-adherence was 
related to specific types of concern. Patient concerns, long-term ef-
fect	and	experiencing	side	effects	appear	more	pivotal	in	determin-
ing non-adherence than both level of LDL and cholesterol.
ACKNOWLEDG EMENT
We thank all workers at health clinics at Ramallah and Bethlehem 
who helped in finishing this study and also we thank the participants 
who willingly accepted to share for the purpose of this study.
DISCLOSURE S
None.
AUTHOR CONTRIBUTIONS
All	 authors	 contributed	 to	 study	 conduct	 and	 design.	MK	 and	 JS	
oversaw	study	design,	HA	and	DA	acquired	data.	All	authors	inter-
preted	data.	HH	and	MK	prepared	and	revised	the	manuscript.	All	
authors read and approved the final manuscript.
ORCID
Maher R. Khdour  https://orcid.org/0000-0003-0193-7922 
R E FE R E N C E S
 1. Fodor G. Primary prevention of CVD: treating dyslipidaemia. BMJ 
Clin Evid. 2010;12:2-15.
	 2.	 Alshehri	AM.	Metabolic	syndrome	and	cardiovascular	risk.	J Family 
Community Med. 2010;17:73.
	 3.	 Mishra	RM.	Determinants	of	cardiovascular	disease	and	sequential	
decision-making for treatment among women: a Heckman's ap-
proach. SSM Popul Health. 2019;7:100365.
	 4.	 Robitaille	 C.	 Illness	 representations:	 theoretical	 foundations.	
In: Perceptions of Health Illness: Current Research Applications; 
1997:19-45.
 5. Jimmy B, Jose J. Patient medication adherence: measures in daily 
practice. Oman Med J. 2011;26:155-159.
 6. Robinson LB. Beliefs about cholesterol lowering drugs and medi-
cation adherence among rural adults with hypercholesterolemia. 
Online J Rural Nurs Health Care. 2015;15.
	 7.	 Chapman	SC,	Horne	R,	Chater	A,	Hukins	D,	Smithson	WH.	Patients'	
perspectives on antiepileptic medication: relationships between 
beliefs about medicines and adherence among patients with epi-
lepsy	in	UK	primary	care.	Epilepsy Behav.	2014;31:312-320.
	 8.	 Horne	R,	Chapman	SC,	Parham	R,	Freemantle	N,	Forbes	A,	Cooper	
V.	Understanding	patients'	adherence-related	beliefs	about	medi-
cines prescribed for long-term conditions: a meta-analytic review 
of the Necessity-Concerns Framework. PLoS ONE. 2013;8:e80633.
	 9.	 Clyne	 B,	 Cooper	 JA,	 Boland	 F,	 Hughes	 CM,	 Fahey	 T,	 Smith	 SM.	
Beliefs about prescribed medication among older patients with 
polypharmacy:	 a	mixed	methods	 study	 in	 primary	 care.	Br J Gen 
Pract. 2017;67:e507-e518.
	10.	 Bosworth	HB,	Ngouyombo	B,	Liska	J,	Zullig	LL,	Atlani	C,	Beal	AC.	
The importance of cholesterol medication adherence: the need for 
behavioral change intervention programs. Patient Prefer Adherence. 
2018;12:341-348.
	11.	 Lam	WY,	Fresco	P.	Medication	adherence	measures:	an	overview.	
Biomed Res Int. 2015;2015:1-12.
	12.	 Uchmanowicz	 B,	 Jankowska	 EA,	 Uchmanowicz	 I,	 Morisky	 DE.	
Self-reported	medication	adherence	measured	with	Morisky	med-
ication adherence scales and its determinants in hypertensive pa-
tients	aged	≥60	years:	a	systematic	review	and	meta-analysis.	Front 
Pharmacol. 2019;10:1-11.
	13.	 Horne	R,	Weinman	J,	Hankins	M.	The	beliefs	about	medicines	ques-
tionnaire: the development and evaluation of a new method for as-
sessing the cognitive representation of medication. Psychol Health. 
1999;14:1-24.
	14.	 Alhalaiqa	F,	Deane	K,	Nawafleh	A,	Clark	A,	Gray	R.	Adherence	ther-
apy for medication non-compliant patients with hypertension: a 
randomised controlled trial. J Hum Hypertens. 2012;26:117-126.
	15.	 Emilsson	M,	Gustafsson	PA,	Öhnström	G,	Marteinsdottir	I.	Beliefs	
regarding medication and side effects influence treatment adher-
ence in adolescents with attention deficit hyperactivity disorder. 
Eur Child Adolesc Psychiatry. 2017;26:559-571.
8 of 8  |     SHAKARNEH Et Al.
	16.	 Park	HY,	Seo	SA,	Yoo	H,	Lee	K.	Medication	adherence	and	beliefs	
about medication in elderly patients living alone with chronic dis-
eases. Patient Prefer Adherence. 2018;12:175-181.
	17.	 Babu	RH,	Nagaraju	R,	Prasad	K,	Reddy	S.	Assessment	of	medica-
tion adherence and quality of life in hyperlipidemia patients. Int J 
Pharma Bio Sci. 2012;1:388-393.
	18.	 Elsous	A,	Radwan	M,	Al-Sharif	H,	Abu	MA.	Medications	adherence	
and associated factors among patients with type 2 diabetes mellitus 
in the Gaza Strip, Palestine. Front Endocrinol. 2017;8:100.
	19.	 Jackson	 IL,	 Adibe	MO,	Okonta	MJ,	Ukwe	CV.	Medication	 adher-
ence in type 2 diabetes patients in Nigeria. Diabetes Technol Ther. 
2015;17:398-404.
	20.	 Bizu	G,	Habte	BM.	Effect	of	medications-related	beliefs	on	adher-
ence to treatment of type II diabetes mellitus in a primary health-
care	setting,	Addis	Ababa,	Ethiopia.	Int J Pharm Sci Res.	2016;7:144.
	21.	 Sweileh	WM,	Zyoud	SH,	Abu	Nab'a	RJ,	et	al.	Influence	of	patients'	
disease knowledge and beliefs about medicines on medication ad-
herence: findings from a cross-sectional survey among patients with 
type 2 diabetes mellitus in Palestine. BMC Public Health.	2014;14:94.
	22.	 Jamous	 RM,	 Sweileh	 WM,	 Abu-Taha	 AS,	 Sawalha	 AF,	 Zyoud	
SH,	 Morisky	 DE.	 Adherence	 and	 satisfaction	 with	 oral	 hypo-
glycemic medications: a pilot study in Palestine. Int J Clin Pharm. 
2011;33:942-948.
	23.	 Coe	AB,	Moczygemba	LR,	Gatewood	SB,	Osborn	RD,	Matzke	GR,	
Goode	 J-VR.	 Medication	 adherence	 challenges	 among	 patients	
experiencing	homelessness	in	a	behavioral	health	clinic.	Res Social 
Adm Pharm. 2015;11:e110-e120.
	24.	 Osborn	CY,	Mayberry	 LS,	Wagner	 JA,	Welch	GW.	 Stressors	may	
compromise medication adherence among adults with diabetes and 
low socioeconomic status. West J Nurs Res.	2014;36:1091-1110.
	25.	 Ward	NC,	Watts	GF,	Eckel	RH.	Statin	toxicity:	mechanistic	insights	
and clinical implications. Circ Res.	2019;124:328-350.
	26.	 Cohen	JD,	Brinton	EA,	Ito	MK,	Jacobson	TA.	Understanding	Statin	
Use	 in	America	and	Gaps	 in	Patient	Education	 (USAGE):	an	 inter-
net-based survey of 10,138 current and former statin users. J Clin 
Lipidol. 2012;6:208-215.
	27.	 Koh	JJK,	Cheng	RX,	Yap	Y,	et	al.	Access	and	adherence	to	medica-
tions for the primary and secondary prevention of atherosclerotic 
cardiovascular disease in Singapore: a qualitative study. Patient 
Prefer Adherence.	2018;12:2481-2498.
	28.	 Lansberg	P,	Lee	A,	Lee	Z-V,	Subramaniam	K,	Setia	S.	Nonadherence	
to	statins:	individualized	intervention	strategies	outside	the	pill	box.	
Vasc Health Risk Manag.	2018;14:91-102.
 29. Chakrabarti S. What's in a name? Compliance, adherence and concor-
dance in chronic psychiatric disorders. World J Psychiatry.	2014;4:30.
	30.	 Leclerc	 E,	Mansur	 RB,	 Brietzke	 E.	Determinants	 of	 adherence	 to	
treatment in bipolar disorder: a comprehensive review. J Affect 
Disord.	2013;149:247-252.
	31.	 Montes	JM,	Maurino	J,	de	Dios	C,	Medina	E.	Suboptimal	treatment	
adherence in bipolar disorder: impact on clinical outcomes and 
functioning. Patient Prefer Adherence.	2013;7:89-94.
	32.	 Eker	F,	Harkın	S.	Effectiveness	of	six-week	psychoeducation	pro-
gram on adherence of patients with bipolar affective disorder. J 
Affect Disord.	2012;138:409-416.
	33.	 Zelko	E,	Klemenc-Ketis	Z,	Tusek-Bunc	K.	Medication	adherence	in	
elderly with polypharmacy living at home: a systematic review of 
existing	studies.	Materia Sociomed. 2016;28:129-132.
	34.	 Cárdenas-Valladolid	 J,	 Martín-Madrazo	 C,	 Salinero-Fort	 MA,	
de-Santa	 Pau	 EC,	 Abánades-Herranz	 JC,	 de	 Burgos-Lunar	 C.	
Prevalence of adherence to treatment in homebound elderly peo-
ple in primary health care. Drugs Aging.	2010;27:641-651.
	35.	 Lemstra	M,	Alsabbagh	MW.	Proportion	and	risk	indicators	of	non-
adherence to antihypertensive therapy: a meta-analysis. Patient 
Prefer Adherence.	2014;8:211-218.
	36.	 Nicklas	 LB,	 Dunbar	 M,	 Wild	 M.	 Adherence	 to	 pharmacological	
treatment of non-malignant chronic pain: the role of illness percep-
tions and medication beliefs. Psychol Health. 2010;25:601-615.
	37.	 McCracken	LM,	Velleman	SC.	Psychological	flexibility	in	adults	with	
chronic pain: a study of acceptance, mindfulness, and values-based 
action in primary care. Pain.	2010;148:141-147.
	38.	 Brown	MT,	Bussell	JK,	editors.	Medication	adherence:	WHO	cares?	
Mayo Clin Proc.	2011;	86:304-314.
	39.	 Jarab	AS,	Mukattash	TL,	Al-Azayzih	A,	Khdour	M.	A	 focus	group	
study	of	patient's	perspective	and	experiences	of	type	2	diabetes	
and its management in Jordan. Saudi Pharm J. 2018;26:301-305.
	40.	 van	 Driel	 ML,	 Morledge	 MD,	 Ulep	 R,	 Shaffer	 JP,	 Davies	 P,	
Deichmann R. Interventions to improve adherence to lipid-lowering 
medication. Cochrane Database Syst Rev. 2016;12.
	41.	 Mukattash	 TL,	 Alzoubi	 KH,	 Abu	 El-Rub	 E,	 et	 al.	 Prevalence	 of	
non-adherence among psychiatric patients in Jordan, a cross sec-
tional study. Int J Pharm Pract.	2016;24:217-221.
	42.	 Eussen	SRBM,	Elst	MEVD,	Klungel	OH,	et	al.	A	pharmaceutical	care	
program to improve adherence to statin therapy: a randomized con-
trolled trial. Ann Pharmacother.	2010;44:1905-1913.
	43.	 Ho	PM,	Lambert-Kerzner	A,	Carey	EP,	et	al.	Multifaceted	interven-
tion to improve medication adherence and secondary prevention 
measures after acute coronary syndrome hospital discharge: a ran-
domized clinical trial. JAMA Intern Med.	2014;174:186-193.
	44.	 Ma	Y,	Ockene	 IS,	Rosal	MC,	Merriam	PA,	Ockene	 JK,	Gandhi	PJ.	
Randomized trial of a pharmacist-delivered intervention for improv-
ing lipid-lowering medication adherence among patients with coro-
nary heart disease. Cholesterol. 2010;2010:1-11.
How to cite this article:	Shakarneh	JK,	Hallak	HO,	Awadallah	
HB,	Al-Hamed	DH,	Khdour	MR.	Necessity	and	concerns	
about lipid-lowering medical treatments and risk factors for 
non-adherence:	A	cross-sectional	study	in	Palestine.	Int J Clin 
Pract. 2020;00:e13511. https://doi.org/10.1111/ijcp.13511
